They certainly don't seem overly hungry for success, but I admit I don't know what's going on other than through the conference calls. Whatever your feelings about their management team, they certainly don't have much of a "bench"...very, very thin. I have always felt management will conclude the "time for a buyout" will come when Rubin and Sunil are ready for retirement. The board is made up of retired Pharma executives, and Rubin and Sunil in their mid-60's...so I would guess in a couple of years.
News 
Market Data 
Discover 
